Cargando…

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

SIMPLE SUMMARY: Clinical management of ovarian cancer remains a major clinical challenge as many patients develop resistance to standard platinum-based chemotherapy drugs over time. Testing novel targeted strategies and combination therapies may open the door to new possibilities for the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neal, Adam, Lai, Tiffany, Singh, Tanya, Rahseparian, Neela, Grogan, Tristan, Elashoff, David, Scott, Peter, Pellegrini, Matteo, Memarzadeh, Sanaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657291/ https://www.ncbi.nlm.nih.gov/pubmed/34885017 http://dx.doi.org/10.3390/cancers13235908

Ejemplares similares

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Evaluation of risk stratification program based on trajectories of functional capacity in patients with acute coronary syndrome: The REACP study
por: Li, Dongze, et al.
Publicado: (2022)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Exploring the Potential of Drug Response Assays for Precision Medicine in Ovarian Cancer
por: Singh, Tanya, et al.
Publicado: (2020)

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line
por: Nunes, Mariana, et al.
Publicado: (2022)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
por: Hatano, Yuichiro, et al.
Publicado: (2018)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

ACP basic statistics = ACP, statistiques de base.
Publicado: (1985)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
por: Bischof, Katharina, et al.
Publicado: (2019)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer
por: Park, Eunhyang, et al.
Publicado: (2022)

Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia
por: Neal, Adam S., et al.
Publicado: (2020)

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018)

GCNCPR-ACPs: a novel graph convolution network method for ACPs prediction
por: Wu, Xiujin, et al.
Publicado: (2022)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
por: Zhang, Jing, et al.
Publicado: (2021)

DLFF-ACP: prediction of ACPs based on deep learning and multi-view features fusion
por: Cao, Ruifen, et al.
Publicado: (2021)

Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma
por: Kang, Hyo Jeong, et al.
Publicado: (2013)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
por: Hayano, Takahide, et al.
Publicado: (2014)

Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma
por: Orachum, Panarat, et al.
Publicado: (2022)

p53 codon 72 polymorphism and coronary artery disease: Evidence of interaction with ACP(1)
por: Gloria-Bottini, Fulvia, et al.
Publicado: (2012)

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
por: Wong-Brown, Michelle W., et al.
Publicado: (2022)

ACP medicine : a publication of the American College of Physicians /
Publicado: (2004)

The Interactions of CPP–ACP with Saliva
por: Huq, Noorjahan Laila, et al.
Publicado: (2016)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
por: Gershenson, David M., et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

ACP Conference on Fundamental Physics of Ferroelectrics
por: Cohen, Ronald E
Publicado: (2000)

Maryland ACP Winning Abstracts 2017
Publicado: (2017)

Intraarticular ACP therapy for severe osteoarthritis
por: Borsky, Michael
Publicado: (2019)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Shewanella oneidensis FabB: A β-ketoacyl-ACP Synthase That Works with C16:1-ACP
por: Luo, Qixia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pj16to9f7gl395svr65vkkghip